Jules Bordet Institute
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Private
- Established
- 1939-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.bordet.be
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Phase 2
Recruiting
- Conditions
- MelanomaBreast CancerNon Small Cell Lung CancerNon-melanoma Skin CancerHead and Neck CancerMSI-H Colorectal CancerGastrointestinal CancerSmall Cell Lung CancerMerkel Cell CarcinomaMesothelioma, Malignant
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 441
- Registration Number
- NCT05429866
- Locations
- 🇧🇪
Institut Jules Bordet, Brussel, Anderlecht, Belgium
Advanced Cancer Patients' and Their Primary Caregivers' Willingness to Communicate About Advance Care Planning (ACP)
Recruiting
- Conditions
- Advanced Cancer
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 600
- Registration Number
- NCT05426330
- Locations
- 🇧🇪
Institut Jules Bordet, Bruxelles, Belgium
COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2
Phase 4
Terminated
- Conditions
- Cancer
- First Posted Date
- 2021-10-12
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 152
- Registration Number
- NCT05075538
- Locations
- 🇧🇪
Institut Jules Bordet, Anderlecht, Belgium
🇧🇪CHU UCL Namur Sainte-Elisabeth, Namur, Belgium
Inferior Epigastric Lymph Node in Colorectal Carcinosis
Not Applicable
Completed
- Conditions
- Colorectal Carcinomatosis
- Interventions
- Procedure: Epigastric lymph node biopsy
- First Posted Date
- 2021-07-19
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 20
- Registration Number
- NCT04966715
- Locations
- 🇧🇪
Jules Bordet Institute, Brussels, Belgium
Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Jules Bordet Institute
- Registration Number
- NCT04856475
Micro-wave Ablation Under Organ-based Tracking in Patients With Prostate Cancer - FOSTINE
Not Applicable
- Conditions
- Focal Treatment for Prostate Cancer
- Interventions
- Device: Micro-wave ablation
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2021-04-05
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 10
- Registration Number
- NCT04831905
- Locations
- 🇧🇪
Institut Jules Bordet, Bruxelles, Belgium
ProCaLung: Project on Cancer of the Lung
Recruiting
- Conditions
- Locally Advanced Lung Carcinoma
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 1000
- Registration Number
- NCT04726358
- Locations
- 🇧🇪
AZ Sint-Maarten, Mechelen, Belgium
🇧🇪AZ Turnhout (campus Sint-Elisabeth), Turnhout, Belgium
🇧🇪Institut Jules Bordet, Brussels, Belgium
De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade
Phase 2
Terminated
- Conditions
- HER2-positive Breast CancerER-Negative Breast CancerPR-Negative Breast CancerNode-negative Breast Cancer
- Interventions
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 139
- Registration Number
- NCT04675827
- Locations
- 🇫🇷
Institut Curie - Paris, Paris, France
🇫🇷CH Perpignan, Perpignan, France
🇫🇷CHU Poitiers, Poitiers, France
Efficacy of the Mepitel® Film on the Prevention of Radiodermatitis in the Inguinal Fold.
Phase 1
Not yet recruiting
- Conditions
- Radiotherapy Side EffectRadiodermatitisRadiation Toxicity
- Interventions
- Other: Flamigel®Device: Mepitel® film
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 35
- Registration Number
- NCT04617730
A Mixed Method to Study Adherence to Oral Anticancer Medications in a Multilingual and Multicultural Setting
- Conditions
- AdultsOral Antineoplastic AgentsHematological Malignancy
- Interventions
- Behavioral: Measure adherence behaviors
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 113
- Registration Number
- NCT04613765
- Locations
- 🇧🇪
CHU Saint Pierre, Brussels, Belgium
🇧🇪Institut Jules Bordet, Brussels, Belgium
© Copyright 2025. All Rights Reserved by MedPath